Fresh Tracks Therapeutics... (FRTX)
Fresh Tracks Therapeutics Statistics
Share Statistics
Fresh Tracks Therapeutics has 5.97M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 5.97M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 4.13M |
| Failed to Deliver (FTD) Shares | 806 |
| FTD / Avg. Volume | 34.88% |
Short Selling Information
The latest short interest is 50.18K, so 0.84% of the outstanding shares have been sold short.
| Short Interest | 50.18K |
| Short % of Shares Out | 0.84% |
| Short % of Float | 1.21% |
| Short Ratio (days to cover) | 0.69 |
Valuation Ratios
The PE ratio is -0.91 and the forward PE ratio is -0.17.
| PE Ratio | -0.91 |
| Forward PE | -0.17 |
| PS Ratio | 0.65 |
| Forward PS | null |
| PB Ratio | 0.52 |
| P/FCF Ratio | -1.2 |
| PEG Ratio | n/a |
Enterprise Valuation
Fresh Tracks Therapeutics Inc. has an Enterprise Value (EV) of -5.67M.
| EV / Earnings | 1 |
| EV / Sales | -0.71 |
| EV / EBITDA | 1 |
| EV / EBIT | 0.89 |
| EV / FCF | 1.31 |
Financial Position
The company has a current ratio of 6.98, with a Debt / Equity ratio of 0.
| Current Ratio | 6.98 |
| Quick Ratio | 6.98 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -1272 |
Financial Efficiency
Return on equity (ROE) is -0.57% and return on capital (ROIC) is -64.05%.
| Return on Equity (ROE) | -0.57% |
| Return on Assets (ROA) | -0.49% |
| Return on Capital (ROIC) | -64.05% |
| Revenue Per Employee | 2.00M |
| Profits Per Employee | -1.42M |
| Employee Count | 4 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -4.42% in the last 52 weeks. The beta is 0.48, so Fresh Tracks Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.48 |
| 52-Week Price Change | -4.42% |
| 50-Day Moving Average | 0.72 |
| 200-Day Moving Average | 0.82 |
| Relative Strength Index (RSI) | 84.97 |
| Average Volume (20 Days) | 2.31K |
Income Statement
In the last 12 months, Fresh Tracks Therapeutics had revenue of 8.01M and earned -5.69M in profits. Earnings per share was -0.96.
| Revenue | 8.01M |
| Gross Profit | 8.01M |
| Operating Income | -6.36M |
| Net Income | -5.69M |
| EBITDA | -5.65M |
| EBIT | -6.36M |
| Earnings Per Share (EPS) | -0.96 |
Balance Sheet
The company has 10.87M in cash and 0 in debt, giving a net cash position of 10.87M.
| Cash & Cash Equivalents | 10.87M |
| Total Debt | 0 |
| Net Cash | 10.87M |
| Retained Earnings | -172.16M |
| Total Assets | 11.59M |
| Working Capital | 9.90M |
Cash Flow
In the last 12 months, operating cash flow was -4.34M and capital expenditures 0, giving a free cash flow of -4.34M.
| Operating Cash Flow | -4.34M |
| Capital Expenditures | 0 |
| Free Cash Flow | -4.34M |
| FCF Per Share | -0.73 |
Margins
Gross margin is 100%, with operating and profit margins of -79.44% and -71.12%.
| Gross Margin | 100% |
| Operating Margin | -79.44% |
| Pretax Margin | -71.12% |
| Profit Margin | -71.12% |
| EBITDA Margin | -70.55% |
| EBIT Margin | -79.44% |
| FCF Margin | -54.25% |
Dividends & Yields
FRTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -103.23% |
| FCF Yield | -77.97% |
Analyst Forecast
Currently there are no analyst rating for FRTX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jul 5, 2022. It was a backward split with a ratio of 1:45.
| Last Split Date | Jul 5, 2022 |
| Split Type | backward |
| Split Ratio | 1:45 |
Scores
| Altman Z-Score | -19.25 |
| Piotroski F-Score | 4 |